More Stories

Informist, Tuesday, Jul. 21, 2026

 

Please click here to read all liners published on this story

--Granules India Apr-Jun consol net profit INR 1.80 bln 
--Granules India Apr-Jun consol revenue INR 14.77 bln 
--Granules India Apr-Jun consol PAT INR 1.80 bln vs INR 1.13 bln year ago 
--Granules India Apr-Jun consol revenue INR 14.77 bln vs INR 12.10 bln yr ago 
--Granules India Q1 consol EBITDA INR 3.39 bln vs INR 2.47 bln yr ago 
--Granules India Apr-Jun consol EBITDA margin 23% vs 20% yr ago 
--Granules India Q1 R&D spends INR 880 mln, up 30% on yr, 6% of sales 

 

By Pratyush Kumar

 

MUMBAI – Pharmaceutical manufacturer Granules India Ltd. reported a sharp rise in its revenue from operations and net profit for the June quarter Tuesday, beating analysts' estimates.

 

The company reported a consolidated net profit of INR 1.80 billion for the June quarter, up 60% on year. The net profit was down nearly 11% sequentially. Granules India reported a consolidated revenue from operations of INR 14.77 billion for the June quarter, up 22% on year and slightly higher on quarter.

 

Granules reported earnings before interest, tax, depreciation, and amortisation of INR 3.39 billion for the June quarter, up 37% on year.

 

Total expenses for the quarter under review stood at INR 12.39 billion, up 17% on year and mildly up on quarter. The cost of material consumed, which is the company's biggest expense, was INR 4.95 billion, up 16% on year but down more than 23% sequentially.

 

"Q1 FY27 (June quarter) marks an important step forward for Granules India as the foundations strengthened during FY26 begin to translate into greater execution confidence, strategic clarity and business resilience," Krishna Prasad Chigurupati, chairman and managing director said. "...While external cost pressures and supply chain volatility require continuous management for next couple of quarters, we are continuing to invest in R&D largely towards Complex Gx (complex generics), digitalization, operational excellence, sustainability and talent to support long-term value creation."

 

Granules reported EBITDA margin of 22.9% for the June quarter, up 256 basis points on year. The comapny's net debt-to-EBITDA for the quarter in review improved to 0.07 time from 0.34 time on Mar. 31. 

 

The company's return on capital employed improved to 18%, up 196 bps on year, due to an increase in contribution from the complex generics portfolio. Granules expects its Genome Valley and peptide contract development and manufacturing organisation to aid upside returns in the medium term. The company said its capex moderated in the June quarter as the Genome Valley investment was completed. The growth was driven by a higher complex generics finished-dosage, increasing to 50% on year from 39%, the company added.

 

Granules India completed five finished dosage filings and four active pharmaceutical ingredient filings in the June quarter. The company's investment in research and development stood at 6% of sales at INR 880 million in the June quarter, aiding high-value pipeline and future growth opportunities.

 

The company filed three dossiers for integrated generics and two dossiers for complex generics in the June quarter. Granules' Gagillapur plant status is under re-inspection as of the June quarter, according to the company. The plant makes 26.8 billion finished dosages and 23,200 tonnes per annum of the pharmaceutical formulation intermediates.

 

At 1341 IST, shares of Granules India traded at INR 875.40 on the National Stock Exchange, slightly down from Monday.  End

 

IST, or Indian Standard Time, is five-and-a-half hours ahead of GMT

 

Edited by Akul Nishant Akhoury

 

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

 

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

 

Informist Media Tel +91 (22) 6985-4000 

Send comments to feedback@informistmedia.com

 

© Informist Media Pvt. Ltd. 2026. All rights reserved.